Tsung-Ta Chiang
Overview
Explore the profile of Tsung-Ta Chiang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai D, Hsieh L, Chung P, Chen Y, Jhou Y, Tseng K, et al.
J Microbiol Immunol Infect
. 2024 Sep;
57(6):947-956.
PMID: 39271437
Background: A predominate azole-resistant Candida tropicalis clade 4 genotype causing candidemia has been detected in not only Taiwan but also China, Singapore, and Australia. It can also be detected on...
2.
Chiang T, Chiang M, Tang H, Shi Z, Ho M, Chou C, et al.
Eur J Clin Microbiol Infect Dis
. 2024 Jul;
43(9):1777-1785.
PMID: 38995342
Background: Infections caused by Klebsiella pneumoniae are common and result in high mortality rates. In vitro studies demonstrated the potency of cefoperazone/sulbactam (CPZ/SUL) against Klebsiella pneumoniae. However, the clinical efficacy...
3.
Chen R, Lu P, Yang T, Lin S, Tang H, Chang F, et al.
J Antimicrob Chemother
. 2024 Feb;
79(3):648-655.
PMID: 38319833
Objective: We aimed to assess the efficacy of cefoperazone/sulbactam (CPZ/SUL) in extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections and identify factors influencing outcomes. Methods: This retrospective multicentre study was conducted in Taiwan...
4.
Chiang T, Huang T, Sun J, Kuo S, Cheng A, Liu C, et al.
Front Cell Infect Microbiol
. 2022 Oct;
12:964539.
PMID: 36189355
In the past decades, due to the high prevalence of the antibiotic-resistant isolates of , it has emerged as one of the most troublesome pathogens threatening the global healthcare system....
5.
Huang R, Chiu C, Shang H, Perng C, Chiang T, Tsai C, et al.
J Microbiol Immunol Infect
. 2022 Sep;
55(6 Pt 1):1036-1043.
PMID: 36057491
Background/purpose: Clinical characteristics of patients in the first community outbreak of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.7 in Taiwan have not been...
6.
Lin S, Lu P, Wu T, Shie S, Chang F, Yang Y, et al.
Infect Dis Ther
. 2022 Jul;
11(5):1853-1867.
PMID: 35864347
Introduction: The clinical efficiency of cefoperazone/sulbactam (CPZ/SUL) against Escherichia coli bacteremia was unknown. This study aimed to explore the relationship between CPZ/SUL MIC values and clinical outcomes in Escherichia coli...
7.
Huang R, Chiu C, Chiang T, Tsai C, Wang Y, Chang F, et al.
J Chin Med Assoc
. 2022 Jun;
85(9):922-927.
PMID: 35727096
Background: Coronavirus disease 2019 (COVID-19) inpatients may acquire infections from other pathogens during hospital admission. This is the first research on this subject to be reported from Taiwan. Methods: Confirmed...
8.
Wang Y, Tsai D, Yen L, Yao Y, Chiang T, Chiu C, et al.
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268531
During the coronavirus disease (COVID-19) pandemic, we admitted suspected or confirmed COVID-19 patients to our isolation wards between 2 March 2020 and 4 May 2020, following a well-designed and efficient...
9.
Yin T, Lai J, Huang W, Kuo S, Chiang T, Yang Y
J Chemother
. 2021 Nov;
34(3):166-172.
PMID: 34818987
Several antimicrobial combination therapies are used to treat multiple drug resistant (MDR) and extensively drug resistant (XDR) infections. A novel antibiotic, eravacycline, shows a higher potency than tigecycline. The efficacies...
10.
Huang R, Chiang T, Chiang M, Yang Y
J Formos Med Assoc
. 2020 Oct;
120(5):1274-1275.
PMID: 33127272
No abstract available.